GSK of­fers glimpse at pos­i­tive Phase 3 an­tibi­ot­ic da­ta for uro­gen­i­tal gon­or­rhea

Two months af­ter its uro­gen­i­tal gon­or­rhea an­tibi­ot­ic hit the pri­ma­ry end­point in a reg­is­tra­tional tri­al, GSK is pro­vid­ing a clos­er look at re­sults as it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Senior Associate - Life Science

Alexandria Real Estate Equities

Seattle, WA, USA